Chuang Qi

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

Yongxiang Xia, Weiwei Tang, Xiaofeng Qian et al. · Journal for ImmunoTherapy of Cancer · 2022 · 211 citations · Full text

Medicine, Oncology, Pharmacology +17

Identification of Deleterious <i>NOTCH</i> Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC

Kai Zhang, Xiaohua Hong, Zhengbo Song et al. · Clinical Cancer Research · 2020 · 137 citations

Medicine, Genetics, Oncology +17

Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors

Zhijie Wang, Jianchun Duan, Guoqiang Wang et al. · Journal of Thoracic Oncology · 2019 · 92 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

ABAT and ALDH6A1, regulated by transcription factor HNF4A, suppress tumorigenic capability in clear cell renal cell carcinoma

Jun Lü, Zhan Chen, Hu Zhao et al. · Journal of Translational Medicine · 2020 · 64 citations · Full text

Medicine, Genetics, Oncology +17

&lt;p&gt;Circ_0072995 Promotes Cell Carcinogenesis via Up-Regulating miR-149-5p-Mediated SHMT2 in Breast Cancer&lt;/p&gt;

Chuang Qi, Xianxiong Qin, Zuozhi Zhou et al. · Cancer Management and Research · 2020 · 50 citations · Full text

Medicine, Molecular Biology, Oncology +17